カンジダ症治療薬の世界市場

カンジダ症治療薬の世界市場は2030年までに52億米ドルに達する見込み

2023年に43億米ドルと推定されるカンジダ症治療薬の世界市場は、分析期間2023-2030年にCAGR 3.1%で成長し、2030年には52億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるアゾール薬剤クラス別は、CAGR 3.1%を記録し、分析期間終了時には27億米ドルに達すると予測されます。エキノカンディン類薬剤クラス別セグメントの成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 3.0％で成長予測

米国のカンジダ症治療薬市場は2023年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 3.0%で推移し、2030年には8億4,550万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と2.5%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

世界のカンジダ症治療薬市場- 主要動向と促進要因まとめ

一般にイースト菌感染症として知られるカンジダ症は、カンジダ種によって引き起こされる真菌感染症であり、カンジダ・アルビカンスが最も一般的です。これらの感染症は、口腔の鵞口瘡や膣のイースト菌感染症のような表面的なものから、特に免疫不全の人のような全身的で生命を脅かす可能性のある状態まで様々です。カンジダ症治療薬市場には、アゾール系（フルコナゾールなど）、エキノカンディン系、ポリエン系（アムホテリシンBなど）など、さまざまな抗真菌薬が含まれています。治療状況は、有効性を高め副作用を軽減する新しい製剤やドラッグデリバリーの導入により、年々大きく進化しています。さらに、真菌感染症に対する意識の高まりと早期診断の重要性が、効果的なカンジダ症治療薬への需要に拍車をかけています。

カンジダ症治療薬市場は、その成長軌道を形成している注目すべき動向を目の当たりにしてきました。1つの大きなトレンドは、薬剤耐性カンジダ株の増加であり、そのため新たな抗真菌剤や併用療法の開発が必要となっています。研究者たちは、耐性菌に打ち勝つための新たな作用メカニズムに注目しています。さらに、バイオテクノロジーとゲノミクスの進歩は、新たな薬剤標的の同定と、より効果的な治療法の開発を促進しています。また、個人の遺伝子プロファイルや真菌感染症の特異的な特徴に基づいて治療動向を調整する個別化医療への傾向も強まっています。さらに、遠隔医療やモバイルヘルスアプリなどのデジタルヘルス技術の統合により、患者の治療へのアクセスや投薬レジメンへのアドヒアランスが向上しています。

カンジダ症治療薬市場の成長は、いくつかの要因によってもたらされます。ドラッグ開発やドラッグデリバリーシステムの技術的進歩により、より効率的で的を絞った治療が可能になり、市場が拡大しています。特に高齢化社会とHIV患者や化学療法を受けているがん患者など免疫力が低下している人々の間でカンジダ症の有病率が上昇していることが大きな推進力となっています。さらに、真菌感染症に対する認識や教育的イニシアチブの高まりが早期診断と治療を促し、市場の需要を押し上げています。また、消費者の行動も、再発性感染症に対して医師のアドバイスや市販の治療薬を求める方向にシフトしており、市場の成長に寄与しています。さらに、製薬企業による研究開発への旺盛な投資と、抗真菌薬の迅速な承認に向けた支援的な規制の枠組みが、抗真菌薬市場の革新と拡大を促進しています。

調査対象企業の例（全86件）

• AdvaCare Pharma
• Astellas Pharma Inc
• Atom Pharma
• Cadila Pharmaceuticals Ltd.
• F2G Ltd
• Gilead Sciences, Inc
• GlaxoSmithKline（GSK Plc）
• Matinas BioPharma Holdings, Inc
• Melinta Therapeutics, Inc.
• Merck & Co., Inc
• Pfizer Inc
• Pulmocide Ltd
• SCYNEXIS, Inc.
• Viatris
• Xellia Pharmaceuticals;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Candidiasis Drugs Market to Reach US$5.2 Billion by 2030

The global market for Candidiasis Drugs estimated at US$4.3 Billion in the year 2023, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Azoles Drug Class, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Echinocandins Drug Class segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 3.0% CAGR

The Candidiasis Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$845.5 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Candidiasis Drugs Market - Key Trends and Drivers Summarized

Candidiasis, commonly known as yeast infection, is a fungal infection caused by Candida species, with Candida albicans being the most prevalent. These infections can range from superficial, such as oral thrush and vaginal yeast infections, to systemic and potentially life-threatening conditions, particularly in immunocompromised individuals. The candidiasis drugs market encompasses a variety of antifungal medications, including azoles (like fluconazole), echinocandins, and polyenes (such as amphotericin B). The treatment landscape has evolved significantly over the years with the introduction of new drug formulations and delivery methods that enhance efficacy and reduce side effects. Additionally, the growing awareness about fungal infections and the importance of early diagnosis have spurred the demand for effective candidiasis treatments.

The candidiasis drugs market has witnessed notable trends that are shaping its growth trajectory. One major trend is the increasing incidence of drug-resistant Candida strains, which has necessitated the development of new antifungal agents and combination therapies. Researchers are focusing on novel mechanisms of action to outpace the resistance. Additionally, advancements in biotechnology and genomics are facilitating the identification of new drug targets and the development of more effective treatments. There is also a growing trend towards personalized medicine, where treatments are tailored based on individual genetic profiles and specific characteristics of the fungal infection. Moreover, the integration of digital health technologies, such as telemedicine and mobile health apps, is improving patient access to treatment and adherence to medication regimens.

The growth in the candidiasis drugs market is driven by several factors. Technological advancements in drug development and delivery systems are enabling more efficient and targeted treatments, thus expanding the market. The rising prevalence of candidiasis, particularly among the aging population and those with weakened immune systems, such as HIV patients and cancer patients undergoing chemotherapy, is a significant driver. Additionally, increasing awareness and educational initiatives about fungal infections are prompting early diagnosis and treatment, thereby boosting market demand. Consumer behavior is also shifting towards seeking medical advice and over-the-counter treatments for recurrent infections, contributing to market growth. Furthermore, strong investment in research and development by pharmaceutical companies, along with supportive regulatory frameworks for fast-track approvals of antifungal drugs, is fostering innovation and expansion in the candidiasis drugs market.

Select Competitors (Total 86 Featured) -

• AdvaCare Pharma
• Astellas Pharma Inc
• Atom Pharma
• Cadila Pharmaceuticals Ltd.
• F2G Ltd
• Gilead Sciences, Inc
• GlaxoSmithKline (GSK Plc)
• Matinas BioPharma Holdings, Inc
• Melinta Therapeutics, Inc.
• Merck & Co., Inc
• Pfizer Inc
• Pulmocide Ltd
• SCYNEXIS, Inc.
• Viatris
• Xellia Pharmaceuticals;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Candidiasis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Innovative Antifungal Therapies Propel Growth in Candidiasis Drugs Market
  • Increasing Incidence of Drug-Resistant Strains Expands Addressable Market Opportunity
  • Advancements in Biotechnology and Genomics Strengthen Business Case for Novel Candidiasis Treatments
  • Rising Prevalence of Immunocompromised Conditions Spurs Demand for Effective Candidiasis Medications
  • Telemedicine and Mobile Health Apps Accelerate Demand for Convenient Candidiasis Medications
  • Growing Awareness and Early Diagnosis Throw the Spotlight on Candidiasis Drugs Market
  • Educational Initiatives Propel Growth by Promoting Early Detection and Treatment
  • Focus on Reducing Side Effects Enhances the Business Case for New Antifungal Medications
  • Evolving Drug Delivery Systems Generate Opportunities in the Candidiasis Drugs Market
  • Increasing Healthcare Expenditure Sustains Growth in Demand for Advanced Candidiasis Treatments
  • Innovations in Pharmacogenomics Strengthen Market Position of Personalized Candidiasis Drugs
  • Advancements in Combination Therapies Drive Adoption and Market Growth
  • Rise in Outpatient Treatment Models Propels Demand for Easily Accessible Candidiasis Medications
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Candidiasis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Echinocandins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Drugs Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• JAPAN
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• CHINA
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• EUROPE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• FRANCE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• GERMANY
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030

IV. COMPETITION